Enzymatica Recruits Chief Operating Officer
Published: Jul 14, 2017
Lund, 14 July, 2017
Enzymatica recruits Chief Operating Officer
Enzymatica has recruited Johan Lindvall as Chief Operating Officer and Executive Vice President. He will be responsible for Enzymatica's production, logistics and product development. He has many years of experience in international and Swedish companies in medical devices and high tech.
"There are exciting opportunities for Enzymatica with its patented barrier technology on which the common cold spray ColdZyme® is based. I look forward to being able to contribute with my operational experience in a demanding medical device sector, and in the global market. My goal is to contribute to Enzymatica becoming a respected business partner with an interesting product portfolio," says Johan.
"We are very pleased to have recruited Johan who, with his experience, will play a key role in enabling us to cope with the production volumes and the demands from our international distributors for efficient production and logistics, and in taking responsibility for continued product development," says Fredrik Lindberg, CEO of Enzymatica.
One of Johan Lindvall's previous positions was as Supply Chain Director for the Nordic countries in Biomet, with responsibility for logistics and customer service. Biomet, now Zimmer Biomet, is a world-leading orthopaedic company. Johan Lindvall has also been Plant Director and had assignments in European operations for Biomet. He joins Enzymatica from a position as Deputy CEO and Chief Operating Office of Agellis Group, which develops, manufactures and markets measuring instruments and monitoring equipment for the global metal industry. Johan Lindvall has previously held senior positions in supply chain and product development in companies such as Volvo Excavators AB and Precise Biometrics AB.
For more information, contact:
Fredrik Lindberg, CEO of Enzymatica AB
Tel: +46 (0)708-86 53 70, e-mail email@example.com
About Enzymatica AB
Enzymatica AB is a medical device company that develops and sells medical devices for infection-related diseases. In a short period of time, the company has developed ColdZyme®, a unique mouth spray for the common cold, has launched the product in eight markets and has established it among the top-selling cold products in Swedish kronor terms at Swedish pharmacies. The strategy is to continue to grow by strengthening the company's position in existing markets and expanding into new geographical markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser Bank.